MICRORNA-122 AS A BIOLOGICAL MARKER OF CHRONIC VIRAL HEPATITIS C

Q4 Medicine

International Medical Journal Pub Date : 2020-03-10 DOI:10.37436/2308-5274-2020-1-16

O. Shevchenko-Makarenko, L. Shostakovych-Koretska, V. Dosenko, T. Drevytska

{"title":"MICRORNA-122 AS A BIOLOGICAL MARKER OF CHRONIC VIRAL HEPATITIS C","authors":"O. Shevchenko-Makarenko, L. Shostakovych-Koretska, V. Dosenko, T. Drevytska","doi":"10.37436/2308-5274-2020-1-16","DOIUrl":null,"url":null,"abstract":"New epigenetic markers are being studied in various countries around the world to diagnose, predict, and treat the patients with chronic viral hepatitis C. Epigenetics is currently studying the hereditary changes in gene expression or phenotype that are not related to the changes in DNA sequence. One field of epigenetics is the expression of RNA that does not encode a protein, namely miRNA, which is a molecule 18−22 nucleotides in length that plays a crucial role in regulating gene expression. Circulating miRNAs are a new genetic material that can be isolated from a patient's blood. The expression level of a particular miRNA has different biological and clinical effects. By means of its determination in various miRNAs it is possible to predict development of diseases. In order to study the baseline expression of miRNA−122 in patients with chronic viral hepatitis C with the first HCV genotype, 74 patients were examined. Diagnosis and monitoring of the patients was performed according to the local protocols and bioethical standards. The level of miRNA−122 expression in patients with chronic viral hepatitis C with the first HCV genotype was established by reverse transcription. Studies show that the level of miRNA−122 expression in the patients with HCV and healthy individuals showed significant variability. The obtained data indicate that the expression level of miRNA−122 in patients is 29 times higher than in healthy individuals at p = 0.0001 (U; Z). This can be an additional biomarker as an index of the presence of chronic viral hepatitis C and can be further used in practice. Therefore, the high level of miRNA−122 expression in subjects (≥ 8.771 rel. units (Log10 miR−122 ≥ 0.939 rel. units)) may be the basis for further screening of patients for HCV infection. The prospects of using this index, which will allow to personalize the diagnosis and treatment tactics for patients, that, in turn, will contribute to the implementation of the WHO global strategy for the elimination of viral hepatitis.\n\nKey words: chronic viral hepatitis C, miRNA−122, elimination of viral hepatitis, biological marker.","PeriodicalId":54933,"journal":{"name":"International Medical Journal","volume":"1 1","pages":"72-75"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37436/2308-5274-2020-1-16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

New epigenetic markers are being studied in various countries around the world to diagnose, predict, and treat the patients with chronic viral hepatitis C. Epigenetics is currently studying the hereditary changes in gene expression or phenotype that are not related to the changes in DNA sequence. One field of epigenetics is the expression of RNA that does not encode a protein, namely miRNA, which is a molecule 18−22 nucleotides in length that plays a crucial role in regulating gene expression. Circulating miRNAs are a new genetic material that can be isolated from a patient's blood. The expression level of a particular miRNA has different biological and clinical effects. By means of its determination in various miRNAs it is possible to predict development of diseases. In order to study the baseline expression of miRNA−122 in patients with chronic viral hepatitis C with the first HCV genotype, 74 patients were examined. Diagnosis and monitoring of the patients was performed according to the local protocols and bioethical standards. The level of miRNA−122 expression in patients with chronic viral hepatitis C with the first HCV genotype was established by reverse transcription. Studies show that the level of miRNA−122 expression in the patients with HCV and healthy individuals showed significant variability. The obtained data indicate that the expression level of miRNA−122 in patients is 29 times higher than in healthy individuals at p = 0.0001 (U; Z). This can be an additional biomarker as an index of the presence of chronic viral hepatitis C and can be further used in practice. Therefore, the high level of miRNA−122 expression in subjects (≥ 8.771 rel. units (Log10 miR−122 ≥ 0.939 rel. units)) may be the basis for further screening of patients for HCV infection. The prospects of using this index, which will allow to personalize the diagnosis and treatment tactics for patients, that, in turn, will contribute to the implementation of the WHO global strategy for the elimination of viral hepatitis. Key words: chronic viral hepatitis C, miRNA−122, elimination of viral hepatitis, biological marker.

查看原文本刊更多论文

Microrna-122作为慢性病毒性丙型肝炎的生物学标志物

世界各国正在研究新的表观遗传学标志物，以诊断、预测和治疗慢性病毒性丙型肝炎患者。表观遗传学目前正在研究与DNA序列变化无关的基因表达或表型的遗传变化。表观遗传学的一个领域是不编码蛋白质的RNA的表达，即miRNA，它是一种长度为18-22个核苷酸的分子，在调节基因表达中起着至关重要的作用。循环miRNA是一种新的遗传物质，可以从患者的血液中分离出来。特定miRNA的表达水平具有不同的生物学和临床影响。通过在各种miRNA中的测定，可以预测疾病的发展。为了研究miRNA−122在具有第一个HCV基因型的慢性病毒性丙型肝炎患者中的基线表达，对74名患者进行了检查。根据当地协议和生物伦理标准对患者进行诊断和监测。miRNA−122在具有第一个HCV基因型的慢性病毒性丙型肝炎患者中的表达水平是通过逆转录建立的。研究表明，HCV患者和健康个体的miRNA−122表达水平存在显著差异。所获得的数据表明，miRNA−122在患者中的表达水平是健康个体的29倍，p=0.0001（U；Z）。这可以是作为慢性丙型病毒性肝炎存在的指标的额外生物标志物，并且可以在实践中进一步使用。因此，受试者中miRNA−122的高水平表达（≥8.771 rel.单位（Log10 miR−122≥0.939 rel.单位））可能是进一步筛查HCV感染患者的基础。使用这一指数的前景将使患者的诊断和治疗策略个性化，这反过来将有助于实施世界卫生组织全球消除病毒性肝炎战略。关键词：慢性丙型肝炎，miRNA−122，消除病毒性肝炎，生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Medical Journal 医学-医学：内科

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： The International Medical Journal is intended to provide a multidisciplinary forum for the exchange of ideas and information among professionals concerned with medicine and related disciplines in the world. It is recognized that many other disciplines have an important contribution to make in furthering knowledge of the physical life and mental life and the Editors welcome relevant contributions from them. The Editors and Publishers wish to encourage a dialogue among the experts from different countries whose diverse cultures afford interesting and challenging alternatives to existing theories and practices. Priority will therefore be given to articles which are oriented to an international perspective. The journal will publish reviews of high quality on contemporary issues, significant clinical studies, and conceptual contributions, as well as serve in the rapid dissemination of important and relevant research findings. The International Medical Journal (IMJ) was first established in 1994.